Payment overview · 2025
General Payments
$117.58
6 reported records · 6 companies
Healthcare provider profile · identity verified
Vikas V Desai, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST ISLIP, NY · NPI 1922069012
Verified facts
What the public records show
CMS Open Payments records show Vikas V Desai, MD received $117.58 in general payments during 2025 across 6 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.27 | 28.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.10 | 17.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.32 | 15.6% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $16.03 | 13.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.30 | 13.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.56 | 11.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.58 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 220 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 87 |
| Metformin Hcl | Metformin Hcl | 170 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 77 |
| Alprazolam | Alprazolam | 165 | 66 |
| Losartan Potassium | Losartan Potassium | 137 | 64 |
| Methylprednisolone | Methylprednisolone | 136 | 109 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 72 |
| Azithromycin | Azithromycin | 126 | 92 |
| Simvastatin | Simvastatin | 116 | 46 |
| Omeprazole | Omeprazole | 99 | 48 |
| Lisinopril | Lisinopril | 92 | 40 |
| Ozempic | Semaglutide | 92 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 42 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 91 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 35 |
| Gabapentin | Gabapentin | 83 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 27 |
| Sulindac | Sulindac | 75 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 22 |
| Enalapril Maleate | Enalapril Maleate | 54 | 17 |
| Furosemide | Furosemide | 54 | 26 |
| Meloxicam | Meloxicam | 54 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 23 |
| Eliquis | Apixaban | 47 | 20 |
| Montelukast Sodium | Montelukast Sodium | 47 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 32 |
| Prednisone | Prednisone | 38 | 28 |
| Sildenafil Citrate | Sildenafil Citrate | 38 | suppressed |
| Carvedilol | Carvedilol | 37 | 17 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 37 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Famotidine | Famotidine | 35 | 27 |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Trazodone Hcl | Trazodone Hcl | 34 | 19 |
| Valsartan | Valsartan | 33 | 14 |
| Atenolol | Atenolol | 32 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 15 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 13 |
| Clonazepam | Clonazepam | 24 | 12 |
| Glipizide | Glipizide | 24 | 11 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 13 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | 13 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 16 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.58 · 6 records | Boehringer Ingelheim Pharmaceuticals, Inc. | QULIPTA, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error